EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy

Morten Würtz iD, Kevin Kris Warnakula Olesen iD, Deepak L Bhatt iD, Salim Yusuf, Eva Muehlhofer, John W Eikelboom, Michael Maeng

European Heart Journal - Cardiovascular Pharmacotherapy · 2024

DOI: 10.1093/ehjcvp/pvae017 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2024. Verfasst von Morten Würtz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200, Aarhus, Denmark. Hauptthemen laut MEDLINE: Hemorrhage, Aspirin, Platelet Aggregation Inhibitors, Factor Xa Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Bayer AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Guidelines recommend extended dual pathway inhibition (DPI) with aspirin and rivaroxaban in patients with chronic coronary syndrome (CCS) at high ischaemic risk. The CHADS-P2A2RC score improves risk prediction and enables antithrombotic treatment allocation in these patients. This study evaluated the net clinical benefit of DPI treatment according to baseline risk as classified by the CHADS-P2A2RC score in patients with CCS included in the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial. Methods and results COMPASS patients with CCS (n = 14 670), randomized to aspirin alone or DPI, were stratified according to cardiovascular risk using the CHADS-P2A2RC score. Endpoints were major adverse cardiovascular events (MACE), all-cause death, fatal/critical organ bleeding, and composite adverse events (MACE and bleeding). Net clinical benefit was the 30-month risk difference of MACE and bleeding. Thirty-month incidences of MACE [7.9% vs. 3.9%, hazard ratio (HR) 2.01, 95% confidence interval (CI) 1.83–2.18] and fatal/critical organ bleeding (1.2% vs. 0.8%, HR 1.49, 95% CI 1.06–1.92) were higher in high-risk (CHADS-P2A2RC ≥ 4) than in low/moderate-risk (CHADS-P2A2RC < 4) patients. DPI reduced MACE (low/moderate risk: HR 0.62, 95% CI 0.47–0.82; high risk: HR 0.82, 95% CI 0.68–0.99, P for interaction 0.09) and all-cause death (low/moderate risk: HR 0.65, 95% CI 0.46–0.91; high risk: HR 0.81, 95% CI 0.65–1.00, P for interaction 0.29), without substantially increasing fatal/critical organ bleeding (low/moderate risk: HR 1.35, 95% CI 0.72–2.53; high risk: HR 1.18, 95% CI 0.73–1.90, P for interaction 0.73). DPI provided net clinical benefit of similar magnitude in low/moderate-risk (−1.81%, 95% CI −3.00 to −0.62) and high-risk (−1.96%, 95% CI −3.60 to −0.33) CCS patients.

Conclusion

As classified by the CHADS-P2A2RC score, low/moderate- and high-risk patients with CCS derived similar net clinical benefit and reduction in all-cause death from DPI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemorrhageAspirinPlatelet Aggregation InhibitorsFactor Xa InhibitorsRivaroxabanHumansMaleFemaleAgedRisk AssessmentTreatment OutcomeMiddle AgedTime FactorsChronic DiseasePurinergic P2Y Receptor AntagonistsDual Anti-Platelet TherapyHeart Disease Risk Factors

Stichwörter der Autor:innen

AspirinChronic coronary syndromeCoronary artery diseaseMyocardial infarctionPlatelet inhibitorsRivaroxaban

Substanzen

AspirinPlatelet Aggregation InhibitorsFactor Xa InhibitorsRivaroxabanPurinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200, Aarhus, Denmark.
  • Department of Cardiology, Regional Hospital Gødstrup, Hospitalsparken 15, DK-7400, Herning, Denmark.
  • Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA.
  • Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, L8L 2X2 Ontario, Canada.
  • Research & Development, Bayer AG Pharmaceuticals, 42117 Wuppertal, Germany.
  • Department of Clinical Medicine, Faculty of Health, Aarhus University, DK-8200, Aarhus, Denmark.

ORCID-Profile: Morten Würtz, Kevin Kris Warnakula Olesen, Deepak L Bhatt

Förderung

  • Bayer AG

Zitieren

APA

Würtz, M., Olesen, K. K. W., Bhatt, D. L., Yusuf, S., Muehlhofer, E., Eikelboom, J. W., & Maeng, M. (2024). Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae017

Vancouver

Würtz M, Olesen KKW, Bhatt DL, Yusuf S, Muehlhofer E, Eikelboom JW, et al. Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy. European Heart Journal - Cardiovascular Pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae017

BibTeX
@article{Wrtz2024,
  author = {Würtz, Morten and Olesen, Kevin Kris Warnakula and Bhatt, Deepak L and Yusuf, Salim and Muehlhofer, Eva and Eikelboom, John W and Maeng, Michael},
  title = {Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2024},
  doi = {10.1093/ehjcvp/pvae017}
}
Kostenlos starten →